Abnormal production of inflammatory mediators is believed to play an important role in the pathogenesis of psoriasis. Emerging data, both in mice and in humans, put the spotlight on a new subset of T helper (Th) cells, in part characterized by their production of IL-17 and accordingly named Th17 cells. Here, we review the development, characterization, and function of human Th17 cells as well as the crucial role of IL-23 in the context of Th17-cell-dependent chronic inflammation in psoriasis. We further discuss recent clinical trials targeting the IL-23/Th17 axis in psoriasis.
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease, evolving over time during a complex interplay between environmental and genetic factors. Although, in the past, psoriasis has been considered a primary keratinocyte (KC) disorder, the successful treatment of psoriasis patients with cyclosporin A suggested a potential role of the immune system in the pathogenesis of the disease (Mueller and Herrmann, 1979) . The identification of activated CD4 þ and CD8 þ lymphocytes in psoriatic plaques and blood of psoriatic patients (Bos et al., 1989; De Panfilis et al., 1989; Ferenczi et al., 2000) , the detection of clonally expanded T cells (Vollmer et al., 2001) , and studies of human skin xenografts in mice (WroneSmith and Nickoloff, 1996; Nickoloff and Wrone-Smith, 1999; Boyman et al., 2004) supported the growing evidence that activated T cells are the primary modulators in the pathogenesis of psoriasis. Clinical studies on the therapeutic efficacy of T-cell-targeted drugs further substantiated the role of T cells in psoriasis (Abrams et al., 2000; Goedkoop et al., 2004) . Characterization of cells and cytokines involved in the initiation and maintenance of psoriasis showed elevated levels of IFN-g, tumor necrosis factor (TNF) -a, and IL -12, but not IL-4, IL-5, or IL-10, at both mRNA and protein levels (Nestle et al., 1994; Schlaak et al., 1994; Austin et al., 1999) . These observations led to the new definition of psoriasis as a T helper (Th) 1-type disease (Lew et al., 2004) .
Recently, a new population of IL-17-producing Th cells, accordingly named Th17, has been described and its involvement in model systems of autoimmunity shown (Weaver et al., 2007) . Furthermore, the development and maintenance of Th17 cells have been linked to IL-23, a key initiating cytokine in the development of autoimmunity Kastelein et al., 2007) .
The findings of elevated levels of IL-23 and Th17-related cytokines in cutaneous lesions and in the serum of psoriatic patients, the association of IL23R gene variants with psoriasis, and the evidence of a functional role of Th17 cells in autoimmunity, provide the basis for a rising interest in the IL-23/Th17 axis in psoriasis (Blauvelt, 2008) . In this review, we will discuss the biology and function of the IL-23/Th17 pathway, its potential dysregulation in psoriasis, and the exciting perspective of novel therapeutics targeting the IL-23/ Th17 axis.
BIOLOGY OF IL-23 AND Th17 CELLS IL-23 and the IL-23 receptor
IL-23 was discovered in 2000 by Oppmann and co-workers while searching sequence databases for members of the IL-6 cytokine family (Oppmann et al., 2000) . They identified a new protein designed as IL-23p19, which had no biological activity but, when combined with the IL-12p40 subunit of IL-12, formed a novel heterodimeric cytokine that they named IL-23.
IL-23 was found to be expressed by activated mouse and human monocytes, macrophages, dendritic cells (DCs), T cells, B cells, and endothelial cells (Oppmann et al., 2000; Pirhonen et al., 2002) . IL-23 binds to and signals through its heterodimeric receptor complex composed of IL-12Rb1 and IL-23R subunits (Parham et al., 2002) (Figure 1 ). Whereas IL-12Rb1 is also part of the IL-12 receptor, IL-23R is unique to the IL-23 receptor complex. IL-23R expression on memory T cells, natural killer T cells, monocytes, and DCs correlates with cellular responsiveness to IL-23 (Belladonna et al., 2002; Parham et al., 2002; Rachitskaya et al., 2008) .
Both the IL-12Rb1 and IL-23R chain lack intrinsic signaling activity and are associated with intracellular proteins to induce downstream signaling. IL-12Rb1 binds to the Jak family member, Tyk2, whereas IL-23R associates with Jak2 (Zou et al., 1997; Parham et al., 2002) . IL-23 stimulation results in ligand-induced autophosphorylation and transphosphorylation of receptor-associated Jaks. Jaks in turn phosphorylate tyrosine residues located in the intracellular domain of the receptor subunits. These phosphorylated tyrosine residues serve as docking sites for the signal transducer and activator of transcription (STAT) molecules, which in turn also get phosphorylated. Notably, IL-23 activates a similar spectrum of STATs as IL-12: STAT1, STAT3, STAT4, and STAT5 (Parham et al., 2002) ; however, STAT3 is the main player in the IL-23 signaling pathway, whereas STAT4 is the main player in the IL-12 pathway. Once activated, STAT3 homodimers translocate into the nucleus, where they bind to the DNA in the promoter region of the target genes.
Since its discovery, IL-23 has been linked to the pathogenesis of autoimmune inflammation. Early studies showed that expression of IL-23p19 in multiple tissues of transgenic mice induced systemic inflammation, runting, infertility, and premature death (Wiekowski et al., 2001) . Interestingly, mice lacking IL-23p19 and IL-12p40 subunits, but not those lacking the IL-12p35-specific subunit, are resistant to animal models of autoimmunity, including experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA) (Cua et al., 2003; Murphy et al., 2003) . Furthermore, the development of spontaneous colitis in IL-10-deficient mice is completely prevented by crossing them with IL-23p19-deficient mice (Yen et al., 2006) . These data, together with the observation that IFN-gproducing cells are present in EAE-resistant, IL-23-deficient mice (Langrish et al., 2005) , showed that IL-23-driven immune responses are IFN-g pathway independent and that IL-23, rather than IL-12, is critical for the development of autoimmune disease in these model systems. The expression of IL-23p19 in clinical samples of Crohn's disease (CD) (Schmidt et al., 2005) , rheumatoid arthritis (RA) (Sato et al., 2006) , and multiple sclerosis (MS) patients (Vaknin-Dembinsky et al., 2006; Li et al., 2007 Li et al., , 2008 ) supports a possible role of IL-23 in common human autoimmune diseases.
Robust evidence for a role of the IL-23 pathway in autoimmune diseases comes from recent genetic studies. Taking advantage of recently introduced high-throughput genotyping technologies, a number of genome-wide association studies have been carried out to identify novel susceptibility genes for common complex genetic diseases. We and others have conducted such studies in psoriasis and have identified a non-synonymous nucleotide substitution in exon 9 of the IL23R gene, which results in an arginine to glutamine exchange (Arg381Gln) in the cytoplasmic domain of the receptor, showing a protective role of the variant against psoriasis (Capon et al., 2007; Cargill et al., 2007; Nair et al., 2008) . The same effect has also been clearly documented in CD, ulcerative colitis, (Duerr et al., 2006) , ankylosing spondylitis (Rueda et al., 2008) , graft-versus-host disease (Elmaagacli et al., 2008) , and, with less significant results, also in celiac disease and MS (Nunez et al., 2008) . Additional variants in the IL23R gene have been associated with psoriasis (Cargill et al., 2007; Nair et al., 2008) , RA , Graves' disease (Huber et al., 2008) , and MS (Illes et al., 2008) , thus suggesting that variants in the IL23R gene, may be common determinants of autoimmunity. In addition, we and others have also shown that the IL12B gene, coding for the IL-12p40 subunit of IL-12 and IL-23, is associated with psoriasis (Capon et al., 2007; Cargill et al., 2007) .
Th17 cells and cytokines
Initial studies showed that IL-23 is involved in the proliferation of human and murine memory T cells (Oppmann et al., 2000) ; in contrast, naïve T cells do not respond to IL-23 as they express little or no IL-23R subunit (Parham et al., 2002) . Subsequent studies showed that IL-23 promotes the expansion of the novel Th17 population characterized by the production of IL-17A and other related proinflammatory cytokines (Aggarwal et al., 2003; Harrington et al., 2005; Langrish et al., 2005; Park et al., 2005 Mosmann et al. (1986) (Figure 2 ). IL-17A was originally described as a product of activated memory CD4 þ T cells (Fossiez et al., 1996) , but Infante-Duarte et al.
(2000) provided a first indication in 2000 that IL-17A-producing cells cannot be categorized according to the classical Th1/Th2 paradigm. In fact they showed that CD4 þ T cells, primed with a synthetic peptide in the presence of the spirochete Borrelia burgdorferi, express IL-17A at significantly higher levels than do CD4 þ T cells primed in the presence of IL-12, whereas Th2 cytokines, IL-4 and IL-10, were inhibited under the same conditions (Infante-Duarte et al., 2000) . The concept that the IL-17-producing T cell may be of a distinct T-cell lineage was further strengthened by the discovery of the IL-23 function (Aggarwal et al., 2003) and by gene-targeted mice studies. In IL-23-deficient mice, CIA and EAE resistance correlates well with the absence of IL-17-producing T cells, despite normal induction of IFN-gproducing Th1 cells, thus suggesting that the former are essential for the establishment of autoimmunity Langrish et al., 2005) . Finally, the gene expression analysis of IL-17-producing cells identified a unique expression pattern of proinflammatory mediators, including IL-17A, IL-17F, IL-6, CCL20, and GM-CSF (Langrish et al., 2005) . Definitive arguments pointing toward IL-17-producing cells as a distinct T-cell lineage arose simultaneously from two laboratories, showing that the development of murine Th17 cells from naïve T cells is potently inhibited by IFN-g and IL-4 (Harrington et al., 2005; Park et al., 2005) . During recent years, cytokines and signaling pathways involved in Th17 differentiation have been widely investigated in both mice and humans. Expanding the initial in vivo observations (Aggarwal et al., 2003; Cua et al., 2003; Langrish et al., 2005) , it has been shown later that, in mice, IL-23 alone is not sufficient to drive in vitro Th17 differentiation from naïve T cells as they do not express IL-23R; rather, it acts on the already committed Th17 population. In fact, transforming growth factor (TGF)-b1, together with IL-6, IL-21, and subsequently IL-23, promotes differentiation of Th17 cells from naïve CD4 þ T cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006; Korn et al., 2007) . This finding was initially surprising as TGF-b1 is known to induce the development of regulatory T cells with a potent suppressor function . Consistent with their definition as a bona fide distinct T-cell lineage, the development of Th17 cells does not involve any of the transcription factors implicated in Th1/Th2 differentiation. On the contrary, both in vitro and in vivo differentiation of Th17 cells required the TGF-b1-induced upregulation of the unique lineage-specific transcription factor, ROR (retinoid-related orphan receptor)gt, an orphan nuclear receptor (Ivanov et al., 2006; Zhou et al., 2007) . Furthermore, activation of STAT3 (Mathur et al., 2007; Yang et al., 2007) , as well as involvement of the orphan nuclear receptor RORa (Yang et al., 2008b) and of the aryl hydrocarbon receptor (Quintana et al., 2008; Veldhoen et al., 2008) have been suggested to be important in Th17 development.
A paucity of data regarding Th17 differentiation in humans has been recently rectified by several publications addressing key issues pertinent to possible differences between mouse and human Th17 biology (Chen and O'Shea, 2008) . Early studies had shown that in vitro polarization of human Th17 cells from naïve CD4 þ cells occurs in the presence of toll-like receptor-activated monocytes (Evans et al., 2007) and also that proinflammatory cytokines, such as IL-1b and IL-6, alone or in combination with IL-23, were able to drive Th17 differentiation (Chen et al., 2007; Wilson et al., 2007; Acosta-Rodriguez et al., 2007a) . In particular, IL-1b was sufficient to induce the expression of RORC variant 2, the human ortholog of mouse RORgt, and the production of both IL-17A and IFN-g (Acosta-Rodriguez et al., 2007a), whereas a combination of IL-6 and IL-1b promoted the differentiation of T cells producing IL-17A, but not IFN-g (Acosta- Rodriguez et al., 2007a) . Surface phenotype analysis of these cells showed that IL-17A-producing cells express the chemokine receptors, CCR6 and CCR4, whereas IFN-g/IL-17-producing cells express CCR6 and CXCR3 (Acosta-Rodriguez et al., 2007b) . Recently, CD161 has been found to be expressed in IL-17A-producing cells and has been suggested as a novel surface marker for human Th17 cells (Cosmi et al., 2008) .
However, the most challenging aspect of human Th17 biology is the role of TGFb-1. Although dismissed for a while, an absolute need for TGFb-1 in human Th17 differentiation is now being recognized (O'Garra et al., 2008) . Initial studies showed that TGFb-1 does not promote Th17 differentiation but rather inhibits IL-17A production in a dose-dependent manner (Chen et al., 2007; Wilson et al., 2007; AcostaRodriguez et al., 2007a) . However, recent reports have shown that in humans also, low concentrations of TGFb-1 are necessary to differentiate human naïve CD4 þ T cells into Th17 cells, either in combination with IL-21 (Yang et al., 2008a) , with IL-1b and IL-23 (Manel et al., 2008) or with IL-1b, IL-23, and IL-6 (Volpe et al., 2008) . Although these studies differ slightly in their conclusions about the relative role of proinflammatory mediators, they have collectively shown that, similar to that in mice (Zhou et al., 2008) , TGFb1 concentration and the concomitant presence of at least one proinflammatory cytokine are key factors in human Th17 differentiation. In fact, low concentrations of TGF-b1 synergizes with proinflammatory cytokines such as IL-1b, IL-6, IL-21, and IL-23 (Manel et al., 2008; Yang et al., 2008a) to promote IL-23R expression, thus favoring the differentiation of naïve cells into the Th17 effector lineage, whereas, high levels of TGF-b1 and the absence of inflammatory cytokines would rather inhibit Th17 differentiation, shifting the balance toward regulatory T cell development (Manel et al., 2008) . The presence of a discrete amount of TGF-b1 in the human and bovine serum used in earlier studies probably accounts for the inability to observe TGF-b-induced Th17 differentiation. Finally, using a different approach on the basis of particular genetic traits affecting putative Th17-relevant signals, de Beaucoudrey et al. (2008) have recently confirmed that, among other cytokines, IL-23 is indeed required for an optimal development of human Th17 cells.
In parallel to factors required for Th17 commitment, natural inhibitors of Th17 development have also been identified. As mentioned, both Th1 (IFN-g) and Th2 (IL-4) cytokines inhibit Th17 differentiation (Harrington et al., 2005; Park et al., 2005) . More recently, IL-25, a member of the IL-17 family earlier known as IL-17E and involved in Th2 response (Angkasekwinai et al., 2007) , has been found to negatively regulate Th17 cells by inhibiting the expression of IL-1b and IL-23 by DC (Kleinschek et al., 2007) . Likewise, IL-27, belonging to the IL-6 family (Pflanz et al., 2002) , also acts as a Th17 inhibitor, consistent with its capacity to drive a Th1 cell response (Batten et al., 2006; Stumhofer et al., 2006) .
In addition to IL-17A, Th17 cells have been collectively shown to also produce IL-17F, IL-22, and IL-26, as well as IL-6, IL-21, TNF-a, and IFN-g (Chen et al., 2007; Wilson et al., 2007; Acosta-Rodriguez et al., 2007a; Manel et al., 2008; Volpe et al., 2008) . To date, IL-17A, IL-17F, and IL-26 are considered to be specific Th17 cytokines (Manel et al., 2008) , whereas the others, including IL-22, can be produced by Th1 cells also (Volpe et al., 2008) . In this review, we will focus our attention on those cytokines produced by Th17 cells that have been shown to be of potential relevance to cutaneous inflammation.
Human IL-17A is the founding member of the IL-17 cytokine family, which includes six members, IL-17A to F. Very little is known about IL-17B, IL-17C, and IL-17D, which are produced by non-T-cell sources, whereas IL-17E has been renamed IL-25 and IL-17F shares many features with IL-17A (Weaver et al., 2007) . Although Th17 cells are the major source of IL-17A, other IL-17A-producing cells have also been reported, including CD8 þ cells (Shin et al., 1999) , gd-TCR cells (Roark et al., 2008) , and natural killer T cells (Rachitskaya et al., 2008) . IL-17F shares 50% sequence homology with IL-17A and both cytokines can exist either as IL-17A and IL-17F homodimers or as IL-17A-IL-17F heterodimers (Liang et al., 2007) . They all induce the expression of diverse proinflammatory cytokines (for example, IL-1b and IL-6), colony-stimulating factors (for example, GM-CSF and granulocyte colony-stimulating factors), and chemokines (for example, CXCL8, CXCL1, and CXCL10) from a variety of cells, including monocyte/macrophages, and epithelial cells. Accordingly, IL-17A and IL-17F have potent activity to mobilize, recruit, and activate neutrophils, thus linking adaptive and innate immunity (Weaver et al., 2007) .
IL-22 is a member of the IL-10 cytokines family, and is mainly produced by T and natural killer cells (Wolk et al., 2002) . Neither resting nor activated immune cells respond to IL-22. In contrast, tissue cells at outer body barriers, that is, of the skin, kidney, and the digestive and respiratory systems are targets of this cytokine. IL-22 functions by promoting antimicrobial defense mechanisms, protecting against tissue damage, and re-organizing non-immune tissues, such as epithelia, thus regulating terminal differentiation of KCs (Wolk and Sabat, 2006) .
Functional analysis of Th17 cytokines has revealed an important and unique role for these cytokines in host protection against infections with extracellular pathogens. IL-17R-deficient mice are highly susceptible to infection by the Gram-negative bacterium, Klebsiella pneumoniae, and the fungus, Candida albicans (Ye et al., 2001; Huang et al., 2004) . In addition, the preferential production of IL-17 by T cells during infection by Bacteroides fragilis (Chung et al., , and the fungal species (LeibundGut-Landmann et al., 2007) , suggests that Th17 responses are triggered by specific pathogens and are required for their clearance. These data are supported by recent findings showing that null mutations in IL12B and IL12RB1 genes lead to impaired IL-17-producing T-cell development in patients with autosomal-recessive susceptibility to mycobacterial diseases (de Beaucoudrey et al., 2008) . A number of autoimmune disorders have been associated with overproduction of Th17 cytokines, and interference with their production or action attenuate autoimmune diseases. IL-17-deficient mice are resistant to adjuvant-induced arthritis (Nakae et al., 2003) and develop EAE with delayed onset and reduced severity (Komiyama et al., 2006) . Similarly, IL-17R antagonists (Bush et al., 2002) and IL-17A-blocking antibodies (Abs) (Hofstetter et al., 2005; Langrish et al., 2005) prevent the development of autoimmune diseases.
Under homeostatic conditions, IL-17A is present in extremely low or undetectable concentrations in human sera but has been reported to be overproduced at the both serum and tissue level in inflammatory bowel diseases, MS, and RA; (Kotake et al., 1999; Matusevicius et al., 1999; Lock et al., 2002; Fujino et al., 2003) . Similarly, IL-22-expressing T-cells are present in inflamed regions of the gut in patients with inflammatory bowel diseases but not in the normal colonic mucosa (Andoh et al., 2005) . IL-22 expression was also described in both synovial tissues and in mononuclear cells of the synovial fluid from RA patients (Ikeuchi et al., 2005) .
ROLE OF IL-23 AND TH17 CELLS IN PSORIASIS IL-23 and the IL-23 receptor in psoriasis
The role of IL-23 and IL-23R in cutaneous inflammation has been investigated both in mice and in humans. Intradermal injection of IL-23 in mice led to erythema, induration, and prominent dermal papillary blood vessels with histopathological features resembling psoriasis (Chan et al., 2006) . The morphological features of the IL-23-induced skin lesions were more severe than the ones induced by IL-12 (Zheng et al., 2007) . Furthermore, IL-23 was shown to mediate epidermal hyperplasia, acanthosis, hyperparakeratosis, and orthohyperkeratosis through TNF-a and IL-20R2 (Chan et al., 2006) . In a transgenic mouse model of skin inflammation overexpressing the common IL-12/IL-23 subunit, IL-12p40, under the influence of the keratin 14 promoter, it was shown that IL12p40 and IL-23p19, but not IL-12p35, were constitutively produced by basal KCs (Kopp et al., 2003) . These data were complemented in humans by Lee et al. (2004) showing overexpression of IL-23p19 and IL-12p40, in the absence of IL-12p35, at the mRNA level in psoriatic skin lesions, when compared with that in uninvolved skin. IL-23p19 was mostly localized in the papillary dermis, and it was strongly expressed in monocytes, monocyte-derived DCs, and in mature DCs. Collectively, these data indicate that production of IL-23 occurs at inflammatory skin sites and is mediated by tissue-resident and/or recruited immune cells, such as DCs, and possibly KCs (Piskin et al., 2006) .
Little is known about the immediate downstream effects of IL-23 in psoriasis. IL-23 signals through the IL-23 receptor complex expressed on DCs, lymphocytes, natural killer T cells, and KCs. It has been recently shown that IL-23, in synergy with IL-1b, is able to enhance production of humanb-defensin-2, an antimicrobial peptide increased in psoriasis, in normal human KCs (Kanda and Watanabe, 2008) . Further evidence supporting a pathogenic role of IL-23 in psoriasis comes from the clinical data. Zaba et al. (2007) have shown that anti-TNF-a agents are able to modulate IL-23p19 and IL12p40 mRNA levels, and the inflammatory infiltrate in the psoriatic skin. Furthermore, modulation of IL-23 by cyclosporin A, UV therapy, and by biological agents has been correlated to the clinical benefit in psoriatic patients (Piskin et al., 2004; Gottlieb et al., 2005; Lowes et al., 2008; Haider et al., 2008b) .
Finally, detailed genetic studies of the IL23R gene in psoriasis have recently shown that at least two nonsynonymous single nucleotide polymorphisms, Arg381Gln and proline to leucine (Pro310Leu), independently contribute to a psoriasis phenotype (Capon et al., 2007; Cargill et al., 2007; Nair et al., 2008) . These convincing genetic data, in combination with data showing an association between IL-12B and psoriasis, support the importance of the IL-23 (and possibly IL-12) pathway in psoriasis.
Th17 cells and cytokines in psoriasis
Consistent with the described role of Th17 cells in a variety of chronic inflammatory autoimmune-type diseases, there is a growing body of evidence supporting a major role of Th17 cells and Th17-related cytokines in psoriasis. The first observation that IL-17 could be a relevant cytokine in psoriasis was found in the late 1990s. Teunissen et al. (1998) showed detectable levels of IL-17 mRNA in lesional psoriatic skin, but not in non-lesional skin, and showed that CD4 þ and CD8 þ clones derived from lesional psoriatic skin were able to produce IL-17 after stimulation with CD3/ CD28 Abs. IL-17 was also shown to promote the production of IL-6, IL-8, GM-CSF, and ICAM-1 in KCs, synergizing with IFN-g (Albanesi et al., 2000; Koga et al., 2008) . IL-17-producing cells have been isolated from the dermis of psoriatic lesions (Lowes et al., 2008) . Dermal localization of Th17 cells has also been documented in atopic dermatitis, with a higher percentage of IL-17-producing cells present in acute rather than in chronic lesions (Koga et al., 2008) . Surface phenotypic analysis of IL-17-producing T cells derived from psoriatic skin as well as from intestinal biopsies of patients affected with CD, showed a predominantly CD161 þ phenotype (Cosmi et al., 2008) . DCs isolated from psoriatic skin are able to increase the percentage of IL-17A production in allogenic T cells (Zaba et al., 2009) .
Interestingly, in contrast to other potential Th17-type autoimmune diseases such as RA (Chabaud et al., 1999; Kohno et al., 2008) , CD (Fujino et al., 2003) , MS (Matusevicius et al., 1999) , systemic lupus erythematosus (Wong et al., 2000) , and systemic sclerosis (Kurasawa et al., 2000) , no statistically significant differences in peripheral levels of IL-17A have been found in psoriatic patients when www.jidonline.org 1343 compared with that in controls (Arican et al., 2005) . This suggests that the major site of production of IL-17A in psoriasis may be the lesional skin infiltrated by Th17 cells. This concept is strengthened by the data derived from studies on cytokine profiles after various immunomodulatory treatments in RA and psoriatic patients. In RA, the efficacy of both cyclosporin A and anti-TNF-a therapies has been correlated to modulation of proinflammatory cytokines, both in peripheral blood and in synovia (Cho et al., 2007; Kageyama et al., 2007) . In contrast, in psoriasis, the use of cyclosporin A and anti-TNF-a agents has been reported to decrease cutaneous, but not peripheral, levels of proinflammatory cytokines, such as IFN-g, IL-17A, IL-23p19, and CCL20 (Zaba et al., 2007; Lowes et al., 2008; Haider et al., 2008a, b) .
A key cytokine produced by Th17 cells is IL-22. The role of IL-22 in the pathogenesis of psoriasis has been extensively examined because of its peculiar activities in immune innate response and functions on epithelial cells . IL-22, as well as IL-17, TNF-a, IL-1b, IL-6, IL-12p40, and IL-12, has been found elevated in ear tissues of a psoriasiform mouse model, that is, transgenic K14/VEGF mice treated with 12-O-tetradecanoyl phorbol-13-acetate (Hvid et al., 2008) . IL-23 injection in rodents induces IL-22-dependent dermal inflammation, KC hyperproliferation, and epidermal acanthosis Zheng et al., 2007) . In a CD4 T-celldependent psoriasis mouse model, an IL-22-neutralizing Ab was able to modulate the cutaneous expression of S100A8, S100A9, defensin b1, and cathelicidins, as well as prevent the development of skin lesions .
In vitro studies have shown that IL-22 synergizes with IL-17A and IL-17F to enhance the KC expression of antimicrobial peptides (Liang et al., 2006; Wilson et al., 2007) . IL-22 can also drive epithelial cell release of chemokines, such as IL-8 (Brand et al., 2006; Liang et al., 2006; Koga et al., 2008) , a key factor for neutrophil recruitment into psoriatic lesions. Moreover, in reconstituted human epidermis, KCs express genes involved in tissue repair and wound healing responses on stimulation with IL-22 (Sa et al., 2007) .
Finally, increased IL-22 mRNA and protein levels have been found both in the skin and blood of psoriatic patients Boniface et al., 2007) . IL-22 mRNA levels were higher in lesional skin than in psoriatic peripheral monocytes .
From these data, a concept emerges that IL-17A and IL-22 are key mediators of cutaneous inflammation, linking Th17 pathology with epithelial pathology, thus contributing to the pathogenesis of psoriasis (Figure 3) . The IL-23/Th17 axis model for psoriasis integrates the well-defined type-1 inflammatory pathway model, in which Th1, Tc1 (cytotoxic T cell type-1) lymphocytes, and DCs are the central orchestrators of the events leading to psoriasis (Lew et al., 2004) . The molecular spectrum of the type-1 model of psoriasis is dominated by IL-12, produced by DCs, TNF-a, and IFN-g, released by Th1 and Tc1 lymphocytes, which act on KCs by increasing their proliferation rates and stimulating their ability to release proinflammatory mediators. Typically, in the psoriatic plaque, Th1 lymphocytes are localized in the dermis, whereas Tc1 lymphocytes are mainly found in the epidermis expressing a1b1 integrin (VLA-1, very late antigen-1), which binds to basement membrane collagen IV (Conrad et al., 2007) . Therefore, it can be postulated that, in the psoriatic plaque, dermal dendritic cells produce both IL-12 and IL-23, driving a mixed type-1/Th17 infiltrate that interacts with KCs, fibroblasts, endothelial cells, and neutrophils to create a psoriatic plaque. leading to epidermal hyperplasia, acanthosis, and hyperparakeratosis. Dermal CCR5 þ CXCR3 þ CXCR6 þ Th1 and epidermal VLA-1 þ Tc1 lymphocytes are activated by DDCs and produce TNF-a and IFN-g, contributing to the pathogenesis of the disease. KC hyperproliferation might also be influenced by fibroblasts, which can release keratinocyte growth factor (KGF) through TNF-a stimulation. In the context of this proinflammatory milieu, activated KCs might produce IL-23, which could mediate a cross-talk with Th17 lymphocytes in synergy with IL-23 coming from DDC. Th17 cells induce KC to produce IL-8 and antimicrobial peptides (for example, S100A8, S100A9, and defensin b1/2) for recruitment of neutrophils, cathelicidin for activation of plasmacytoid dendritic cells (PDC), and vascular endothelial growth factor (VEGF) with resulting angiogenesis.
Both CNTO-1275 and ABT-874 are human IgG1 MAbs that bind to the p40 subunit of human IL-12 and IL-23, and prevent its interaction with IL-12Rb1. Preclinical analyses in cynomolgus monkeys, in the monkey asthma model and in the marmoset model for MS, and in vitro studies have been conducted to evaluate the safety of anti-IL-12p40 (Brok et al., 2002; t Hart et al., 2005) . It has also been shown that anti-IL12p40 can lead to a decrease in disease activity in the mouse models of MS (Leonard et al., 1997) and CD (Neurath et al., 1995) . Anti-IL-12p40 successfully abolished psoriatic lesions in mice, even when administered after transfer of the T-cell subset that induced the psoriasis-like condition (Hong et al., 1999; Ma et al., 2008) .
In humans, results from phase I (Kauffman et al., 2004) and phase II studies (Krueger et al., 2007; Kimball et al., 2008) have shown that both CNTO-1275 and ABT-874 can be appropriate treatments for moderate-to-severe psoriasis , being able to modulate IL-8, IL-18, IFN-g, cutaneous lymphocyte antigens (CLA), IL-12R, CD40L, and IL-2Ra expressions and to inhibit the secretion of cytokines induced by IL-12, and IL-23 in psoriasis as well as in CD (Fuss et al., 2006; Toichi et al., 2006; Gottlieb et al., 2007; Reddy et al., 2007) . Indeed, clinical data from phase II studies on anti-IL-12p40 in CD further support IL-12p40 as an appropriate target for CD therapy (Mannon et al., 2004) . Notably, an oral treatment, STA-5326, which acts as a selective transcription inhibitor with potent anti-IL-12 and anti-IL-23 activity, has been reported as effective in preclinical studies on rat and murine models of CD and in a phase I/IIA trial in active moderate-to-severe CD (Burakoff et al., 2006; Wada et al., 2007) .
Currently, several phase III trials have been published or are ongoing to evaluate the efficacy and safety of the anti-IL-12p40 MAb versus placebo or etanercept (anti-TNF-a therapy) in the treatment of moderate-to-severe chronic plaque psoriasis. Leonardi et al. and Papp et al. have published the results of the PHOENIX 1 (Leonardi et al., 2008) and PHOENIX 2 , phase III, randomized, placebo-controlled trials evaluating the efficacy and safety of ustekinumab in moderate-to-severe psoriasis.
The PHOENIX 1 trial assessed the efficacy and safety of ustekinumab 45 and 90 mg, administered subcutaneously at weeks 0, 4, and then every 12 weeks over 76 weeks of treatment. Overall, a larger number of patients in the ustekinumab arm (both 45 and 90 mg) achieved PASI (Psoriasis Area and Severity Index)-75 at week 12 when compared with those in placebo (PASI-75 response in 67.1, 66.4, and 3.1%, respectively). Efficacy increased over time with the maximum effect at week 24 (PASI-75 response observed in 76.1% of patients treated with 45 mg and in 85% of patients in the 90 mg group) and improvement in the PASI score remained stable up to at least week 76. The occurrence of adverse events was similar during the whole duration of the study; it was not statistically different from the placebo group, and did not require treatment adjustment. The most commonly reported adverse events were mild and considered non-serious, and mostly consisted of upper respiratory tract infections, nasopharyngitis, headache, and arthralgia.
The aim of the PHOENIX 2 trial was to assess whether dosing intensification would increase the response to treatment in partial responder patients (between PASI-50 and PASI-75). The results up to week 28 were comparable with the ones reported in PHOENIX 1. At week 28, patients who responded to ustekinumab continued to receive the study agent every 12 weeks and maintained a good response up to week 52. Partial responders at week 28 (22.7 and 15.8% of patients in the 45 and 90 mg group, respectively) were randomly assigned to continue treatment every 12 weeks or, through an intensified regimen, every 8 weeks. Dosing intensification did result in increased clinical efficacy only in patients receiving 90 mg, and not 45 mg, of ustekinumab every 8 weeks (PASI-75 in 68.8% of patients receiving 90 mg every 8 weeks versus 33.3% of patients receiving 90 mg every 12 weeks). The incidence and the kind of adverse events that occurred during the PHOENIX 2 study did not differ from those reported in the PHOENIX 1 trial.
Overall, the results of the clinical studies on the efficacy of anti-IL-12p40 Abs observed so far are promising, suggesting that ustekinumab and possibly ABT-874 could provide a new and effective treatment for moderate-to-severe psoriasis, thus stressing the important role of IL-12/IL-23 in the pathogenesis of the disease. Moreover, anti-IL-12p40 Abs have so far shown a good safety profile during treatment periods of up to 76 weeks. Nevertheless, long-term safety issues are to be considered given the relevant part played by IL-12p40 in host defense (Trinchieri, 1998) , potentially leading to increased susceptibility to infections in patients treated with anti-IL12p40. In humans, mutations in the IL-12p40 subunit or in its receptor have been associated with susceptibility to tuberculosis and salmonella infections, but not to viral or fungal infections de Jong et al., 1998; Oxenius et al., 1999) .
Taken together, targeting both IL-12 and IL-23 is a highly effective therapeutic approach in chronic plaque-type psoriasis. Future studies will show if targeting IL-23 on its own will be effective. Longer follow-up periods with the establishment of treatment registries are necessary to confirm the safety of anti-IL-12p40 Abs in the treatment of moderate-tosevere chronic plaque psoriasis. CONCLUSIONS A significant amount of both clinical and experimental data have established Th17 cells as key players in chronic inflammatory conditions, such as psoriasis, providing an exciting advance in our understanding of psoriasis immunopathogenesis and novel therapeutic targets.
This puts the spotlight on IL-23, which is secreted by skin DCs, and induces production of proinflammatory mediators by Th17 cells such as IL-17A, IL-17F, and IL-22. These mediators will act on KCs leading to their activation and hyperproliferation. In the cross-talk between KC and Th17 cells, activated KCs produce key proinflammatory cytokines, chemokines, and antimicrobial peptides, which are able to recruit and activate immune cells in the inflamed skin. These events result in amplification of the immune response, leading to the clinical features of the disease.
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Integration of the IL-23/Th17 axis into a revised concept of psoriasis pathogenesis has been already translated into novel therapeutic strategies, which are proving to be effective and safe in the treatment of chronic plaque psoriasis. Future investigations will further clarify the role of key components of the IL-23/Th17 axis, and their interplay with other relevant cellular and molecular pathways of the innate and adaptive immune system in psoriasis.
CONFLICT OF INTEREST
Dr Nestle has provided consultant activity to Centocor, Abbott, and Janssen Cilag. The other authors state no conflict of interest.
